Low levels of antibodies against phosphorylcholine predict development of stroke in a population-based study from Northern Sweden

Stroke

Volumn 41, Issue 4, 2010, Pages 607-612

  Fiskesund, Roland ^a   Stegmayr, Birgitta ^b   Hallmans, Göran ^b   Vikström, Max ^c   Weinehall, Lars ^b   De Faire, Ulf ^a   Frostegård, Johan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Immunology; Inflammation

Indexed keywords

ANTIBODY; ANTIHYPERTENSIVE AGENT; CHOLESTEROL; PHOSPHORYLCHOLINE;

ADULT; AGE DISTRIBUTION; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD STORAGE; BODY MASS; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENDER; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RISK FACTOR; SMOKING; STROKE; SWEDEN; WORLD HEALTH ORGANIZATION;

ADULT; AGED; ANTIBODIES; ATHEROSCLEROSIS; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; ODDS RATIO; PHOSPHORYLCHOLINE; RISK FACTORS; STROKE; SWEDEN;

EID: 77950285033     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.109.558742     Document Type: Article

References (36)

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695.
2. Frostegard J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, Andersson U, Hansson GK. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis. 1999;145:33-43.
3. Berliner JA, Territo MC, Sevanian A, Ramin S, Kim JA, Bamshad B, Esterson M, Fogelman AM. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest. 1990;85: 1260-1266.
4. Frostegard J, Nilsson J, Haegerstrand A, Hamsten A, Wigzell H, Gidlund M. Oxidized low density lipoprotein induces differentiation and adhesion of human monocytes and the monocytic cell line U937. Proc Natl Acad Sci USA. 1990;87:904-908.
5. Frostegard J, Wu R, Giscombe R, Holm G, Lefvert AK, Nilsson J. Induction of T-cell activation by oxidized low density lipoprotein. Arterioscler Thromb. 1992;12:461-467.
6. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143.
7. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-Reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.
8. Zalewski A, Nelson JJ, Hegg L, Macphee C. Lp-PLA2: a new kid on the block. Clin Chem. 2006;52:1645-1650.
9. Xu Q, Willeit J, Marosi M, Kleindienst R, Oberhollenzer F, Kiechl S, Stulnig T, Luef G, Wick G. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis. Lancet. 1993;341:255-259.
10. Frostegard J, Lemne C, Andersson B, van der Zee R, Kiessling R, de Faire U. Association of serum antibodies to heat-shock protein 65 with borderline hypertension. Hypertension. 1997;29:40-44.
11. Frostegard J, Kjellman B, Gidlund M, Andersson B, Jindal S, Kiessling R. Induction of heat shock protein in monocytic cells by oxidized low density lipoprotein. Atherosclerosis. 1996;121:93-103.
12. Chou MY, Hartvigsen K, Hansen LF, Fogelstrand L, Shaw PX, Boullier A, Binder CJ, Witztum JL. Oxidation-specific epitopes are important targets of innate immunity. J Int Med. 2008;263:479-488.
13. Binder CJ, Chang MK, Shaw PX, Miller YI, Hartvigsen K, Dewan A, Witztum JL. Innate and acquired immunity in atherogenesis. Nat Med. 2002;8:1218-1226.
14. Frostegard J, Huang YH, Ronnelid J, Schafer-Elinder L. Platelet-activating factor and oxidized LDL induce immune activation by a common mechanism. Arterioscler Thromb Vasc Biol. 1997;17:963-968.
15. Huang YH, Schafer-Elinder L, Wu R, Claesson HE, Frostegard J. Lyso-phosphatidylcholine (LPC) induces proinflammatory cytokines by a platelet-activating factor (PAF) receptor-dependent mechanism. Clin Exp Immunol. 1999;116:326-331.
16. Wu R, Huang YH, Elinder LS, Frostegard J. Lysophosphatidylcholine is involved in the antigenicity of oxidized LDL. Arterioscler Thromb Vasc Biol. 1998;18:626-630.
17. Heery JM, Kozak M, Stafforini DM, Jones DA, Zimmerman GA, McIntyre TM, Prescott SM. Oxidatively modified LDL contains phos-pholipids with platelet-activating factor-like activity and stimulates the growth of smooth muscle cells. J Clin Invest. 1995;96:2322-2330.
18. Su J, Georgiades A, Wu R, Thulin T, de Faire U, Frostegard J. Antibodies of IgM subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension. Atherosclerosis. 2006;188:160-166.
19. Sjoberg BG, Su J, Dahlbom I, Gronlund H, Wikstrom M, Hedblad B, Berglund G, de Faire U, Frostegard J. Low levels of IgM antibodies against phosphorylcholine-A potential risk marker for ischemic stroke in men. Atherosclerosis. 2009;203:528-532.
20. Grönlund H, Hallmans G, Jansson JH, Boman K, Wikström M, Faire Ud, Frostegård J. Low levels of IgM antibodies against phosphorylcholine predict development of acute myocardial infarction in a population based cohort from Northern Sweden. Eur J Cardiovasc Prev Rehabil. 2009;16: 382-386.
21. Wennberg P, Lindahl B, Hallmans G, Messner T, Weinehall L, Johansson L, Boman K, Jansson JH. The effects of commuting activity and occupational and leisure time physical activity on risk of myocardial infarction. Eur J Cardiovasc Prev Rehabil. 2006;13:924-930.
22. Stegmayr B, Lundberg V, Asplund K. The events registration and survey procedures in the Northern Sweden MONICA Project. Scand J Public Health Suppl. 2003;61:9-17.
23. Lenner P, Hallmans G, Weinehall L, Stenling R. [Population-based biological test bank. New possibilities for epidemiologic cancer research]. Lakartidningen. 1991;88:4447-4449.
24. Weinehall L, Hallgren CG, Westman G, Janlert U, Wall S. Reduction of selection bias in primary prevention of cardiovascular disease through involvement of primary health care. Scand J Prim Health Care. 1998; 16:171-176.
25. Truelsen T, Mahonen M, Tolonen H, Asplund K, Bonita R, Vanuzzo D. Trends in stroke and coronary heart disease in the WHO MONICA Project. Stroke. 2003;34:1346-1352.
26. Ohgren B, Weinehall L, Stegmayr B, Boman K, Hallmans G, Wall S. What else adds to hypertension in predicting stroke? An incident case-referent study. J Int Med. 2000;248:475-482.
27. Asplund K, Nasic S, Janlert U, Stegmayr B. Smokeless tobacco as a possible risk factor for stroke in men: a nested case-control study. Stroke. 2003;34:1754-1759.
28. Warlow CP. Epidemiology of stroke. Lancet. 1998;352(suppl 3):SIII1-SIII4.
29. Lindeberg S, Berntorp E, Nilsson-Ehle P, Terent A, Vessby B. Age relations of cardiovascular risk factors in a traditional Melanesian society: the Kitava Study. Am J Clin Nutr. 1997;66:845-852.
30. Frostegard J, Tao W, Georgiades A, Rastam L, Lindblad U, Lindeberg S. Atheroprotective natural anti-phosphorylcholine antibodies of IgM subclass are decreased in Swedish controls as compared to non-westernized individuals from New Guinea. Nutr Metab (Lond). 2007;4:7.
31. Harnett W, Harnett MM. Phosphorylcholine: friend or foe of the immune system? Immunol Today. 1999;20:125-129.
32. Shaw PX, Horkko S, Chang MK, Curtiss LK, Palinski W, Silverman GJ, Witztum JL. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest. 2000;105:1731-1740.
33. Briles DE, Forman C, Hudak S, Claflin JL. Anti-phosphorylcholine antibodies of the T15 idiotype are optimally protective against Streptococcus pneumoniae. J Exp Med. 1982;156:1177-1185.
34. Faria-Neto JR, Chyu KY, Li X, Dimayuga PC, Ferreira C, Yano J, Cercek B, Shah PK. Passive immunization with monoclonal IgM antibodies against phosphorylcholine reduces accelerated vein graft atherosclerosis in apolipoprotein E-null mice. Atherosclerosis. 2006;189:83-90.
35. Caligiuri G, Khallou-Laschet J, Vandaele M, Gaston AT, Delignat S, Mandet C, Kohler HV, Kaveri SV, Nicoletti A. Phosphorylcholine-targeting immunization reduces atherosclerosis. J Am Coll Cardiol. 2007; 50:540-546.
36. Su J, Hua X, Concha H, Svenungsson E, Cederholm A, Frostegard J Natural antibodies against phosphorylcholine as potential protective factors in SLE. Rheumatology (Oxford). 2008;47:1144-1150.